This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OvaScience Appoints David Stern To Executive Vice President, Global Commercial Operations

OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of David Stern to the position of Executive Vice President, Global Commercial Operations, in preparation for the Company’s international introduction of AUGMENT SM. Mr. Stern joins OvaScience from EMD Serono, Inc. (an affiliate of Merck KGaA), where he most recently served as Head Global Business Franchise, Fertility. He will assume his new role in February 2014.

“David is one of the most experienced and talented senior executives in the fertility field, having launched and supported more than ten fertility brands,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. "He has strong relationships with fertility clinics and key opinion leaders worldwide, and his knowledge of the regional dynamics of international in vitro fertilization (IVF) markets will be important as we make AUGMENT available in select clinics outside the U.S. this year.”

“I am joining OvaScience because I am confident that the Company’s egg precursor cell technology platform provides an innovative and unique opportunity to develop new treatment options for fertility patients,” said Mr. Stern. “I look forward to bringing AUGMENT to doctors and patients in international IVF clinics this year, and continuing to introduce additional infertility treatment options in the future.”

Mr. Stern joined EMD Serono in 2003, and rose to the position of Head Global Business Franchise, Fertility, a business with over a billion dollars in revenue annually. Prior to his career at EMD Serono, Mr. Stern had ten years of experience working closely with fertility clinics in sales and marketing roles for Organon Pharmaceuticals. In June 2011, he was recognized as one of the top 30 Emerging Leaders under 45 in the Pharmaceutical Industry by Pharmaceutical Executive magazine. Mr. Stern graduated from Brandeis University and received his M.B.A. from Babson College.

OvaScience also announced that Christopher Bleck will assume the role of Head of Sales and Marketing within the commercial organization. In addition, Alison Lawton, Chief Operating Officer, will be leaving to pursue other opportunities. Dr. Dipp added, “We thank Alison for helping to prepare OvaScience for the launch of its first product and wish her well in her future endeavors.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs